Skip to main content
. 2014 Nov 11;3:1–10. doi: 10.1016/j.bbacli.2014.11.003

Fig. 1.

Fig. 1

Progression-free survival (PFS) for 91 glioblastomas (GBM) and 84 anaplastic gliomas (AG) according to MGMT activity. Tumors were dichotomized by median MGMT activity (5.8 fmol/106 cells for GBMs; 4.1 fmol/106 cells for AGs), and survival curves were calculated by the method of Kaplan–Meier. Greater than median MGMT activity was accompanied by significantly shorter median PFS for GBM (4 vs. 7.5 months; P ≤ 0.0004) and for AGs (12 vs. 43 months; P ≤ 0.0003).